Immunai has raised $20 million in seed funding to develop its machine learning-based platform for mapping the immune system, aiming to enhance cancer treatment options.

Target Information

Immunai, a biotechnology firm, emerged from stealth mode on May 14, 2023, with the ambitious aim of mapping the entire immune system using cutting-edge machine learning technologies. The company has successfully secured $20 million in seed funding to advance its mission, which includes building the world’s largest proprietary dataset of clinical immunological information. Immunai's initiatives focus on enhancing the detection, diagnosis, and treatment of various diseases through a deep understanding of immune cell functions.

The company utilizes single-cell technologies to analyze millions of immune cells, allowing for detailed insights into their behaviors and interactions. Co-founded by Noam Solomon and Luis Voloch in January 2019, Immunai aims to pioneer advancements in cancer immunotherapy—leveraging the complexities of the immune system to develop more effective treatments.

Industry Overview in Israel

Israel has become a focal point for innovation within the biopharmaceutical sector, particularly in the realm of immunotherapy. The nation's robust ecosystem of life sciences is supported by significant investment in research and development, contributing to its reputation as a global leader in